At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Methylene Blue MMX tablets +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Oral Administration of Methylene Blue MMX Tablets on Double-stranded DNA Damage Assessed by GammaH2AX Analysis of Colon Biopsy Samples
In Brief
A Phase 2 clinical trial evaluating standard white light colonoscopy-equivalent to placebo and Methylene Blue MMX tablets for Colorectal Cancer. Completed, enrolled 10 participants across 1 site.
Detailed Summary
Single Centre, open label assignment phase II clinical study. To evaluate the effect of oral 200mg Methylene Blue tablets (administered 8x25mg) prior to endoscopy on double stranded DNA breaks in colonic biopsy samples assessed by histone gamma H2AX analysis, compared to control biopsies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesItaly
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2013
First PostedNov 2014
Primary CompletionDec 2014
TodayJul 2026
First PostedNov 20, 2014
Enrollment StartFeb 1, 2013
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.6 years ago
Interventions
standard white light colonoscopy-equivalent to placeboprocedure
standard white light colonoscopy
Methylene Blue MMX tabletsdrug
8x25mg methylene blue MMX tablets administered before a colonoscopy